 with low-pressure inﬂations
starting with a small balloon to avoid iliac rupture.
Data from the early Food and Drug Administration and
prospective company-sponsored investigational device
exemption trials showed that iliac conduits were used
in 15% to 21% of patients.80,90,189 Improvement in the proﬁle and size of delivery systems has decreased this number signiﬁcantly. An industry-sponsored trial of a TEVAR